Corporate acquisition activity heading into 2027 hinges chiefly on the interest-rate path and corporate balance-sheet strength. Any further Federal Reserve easing that lowers the federal funds rate would reduce financing costs and support higher deal multiples, especially in technology and healthcare where cash-rich buyers dominate. Antitrust enforcement by the FTC and DOJ continues to shape deal pipelines, lengthening timelines for large transactions and favoring smaller or vertical deals. Recent earnings seasons have shown resilient free cash flow at strategic acquirers, while equity valuations and Treasury yields provide real-time signals of buyer appetite. Key catalysts ahead include upcoming FOMC meetings, quarterly results, and any shifts in regulatory guidance that could alter implied probabilities priced by traders.